MARC details
| 000 -LEADER |
|---|
| fixed length control field |
03834nam a22004217a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
240807s20222022 xxu||||| |||| 00| 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
|---|
| International Standard Serial Number |
2218-6778 |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
PMC11093008 [pmc] |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
tbcr-03-37 [pii] |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
Ovid MEDLINE(R) |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| PMID |
38751533 |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
Risk-reducing surgery in PALB2 mutations carriers with breast cancer: a case series and literature review. |
| 251 ## - Source |
|---|
| Source |
Translational Breast Cancer Research : A Journal Focusing on Translational Research in Breast Cancer. 3:37, 2022. |
| 252 ## - Abbreviated Source |
|---|
| Abbreviated source |
Transl Breast Cancer Res. 3:37, 2022. |
| 253 ## - Journal Name |
|---|
| Journal name |
Translational breast cancer research : a journal focusing on translational research in breast cancer |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Year |
2022 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Publication date |
2022 |
| 265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] |
|---|
| Publication status |
epublish |
| 265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] |
|---|
| Medline status |
PubMed-not-MEDLINE |
| 266 ## - Date added to catalog |
|---|
| Date added to catalog |
2024-08-07 |
| 266 ## - Date added to catalog |
|---|
| Date Medline record created |
2024/05/16 03:36 |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
Background: Inherited germline mutations in PALB2 are known to predispose patients to a higher risk of breast, ovarian and pancreatic cancer with an estimated risk of developing breast cancer in over half of all affected women by age 80 years. Current guidelines for screening patients with PALB2 mutations include annual mammograms beginning at age 30 years and consideration of breast magnetic resonance imaging (MRI) and tomosynthesis. Existing evidence regarding risk-reducing surgery with mastectomy is insufficient to make a definitive recommendation to patients. In this case series, we describe the presentation and management of 5 patients with unilateral breast cancer and PALB2 mutations. To our knowledge, this is the first reported case series discussing the role of contralateral risk-reducing mastectomy (CRRM) in breast cancer patients with PALB2 mutations. The aim of our study was to evaluate the challenges in managing breast cancer risk in patients with PALB2 pathogenic variants with illustration through real-world clinical cases and a review of the literature. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
Conclusions: Based on our experience and the currently available literature, CRRM in patients with a PALB2 mutation should be performed on a case-by-case basis through a shared decision-making process taking into consideration overall risk, family history, patient preference and quality of life. Copyright 2022 Translational Breast Cancer Research. All rights reserved. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
Methods: In this retrospective observational study, we present 5 patients with PALB2 mutations between the ages of 29 and 61 years who were diagnosed with breast cancer and underwent surgical management of their breast cancer at our institution between November 2020 and March 2022. Through their clinical courses and a literature review, we discuss the role of CRRM in breast cancer patients with PALB2 gene mutations. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
Results: Out of the 5 patients, 3 patients underwent CRRM and 2 patients chose unilateral surgery for their breast cancer and active surveillance for the contralateral breast. Of the 3 patients who underwent CRRM, 1 patient experienced a surgical complication from reconstruction on the prophylactic side. None of the patients developed any recurrences with an average length of follow up of 15.4 months. |
| 546 ## - LANGUAGE NOTE |
|---|
| Language note |
English |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Indexing |
Automated |
| 656 ## - INDEX TERM--OCCUPATION |
|---|
| Department |
MedStar General Surgery Residency |
| 656 ## - INDEX TERM--OCCUPATION |
|---|
| Department |
MedStar Georgetown University Hospital/MedStar Washington Hospital Center |
| 656 ## - INDEX TERM--OCCUPATION |
|---|
| Department |
Surgery |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Journal Article |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Boisvert, Marc |
| Institution Code |
MWHC |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Masanam, Monika |
| Institution Code |
MGUH |
| Program |
MedStar General Surgery Residency |
| Degree |
MD |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Starks, Leah |
| Institution Code |
MGUH |
| Program |
MedStar General Surgery Residency |
| Degree |
MD |
| 790 ## - Authors |
|---|
| All authors |
Masanam MK, Pitcher CW, Sogunro O, Starks LK, Murray AB, Boisvert ME |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| DOI |
<a href="https://dx.doi.org/10.21037/tbcr-22-33">https://dx.doi.org/10.21037/tbcr-22-33</a> |
| Public note |
https://dx.doi.org/10.21037/tbcr-22-33 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Koha item type |
Journal Article |
| Item type description |
Article |
